Hualan Biological Vaccine Second Quarter 2024 Earnings: CN¥0.022 loss per share (vs CN¥0.024 profit in 2Q 2023)

Simply Wall St · 09/01 00:36

Hualan Biological Vaccine (SZSE:301207) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥1.31m (down 73% from 2Q 2023).
  • Net loss: CN¥13.3m (down by 193% from CN¥14.3m profit in 2Q 2023).
  • CN¥0.022 loss per share (down from CN¥0.024 profit in 2Q 2023).
earnings-and-revenue-growth
SZSE:301207 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hualan Biological Vaccine Earnings Insights

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 17% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Hualan Biological Vaccine, and understanding them should be part of your investment process.